Description
Springer Rhesus haemolytic disease Selected papers and extracts 1st Editon 2012 Softbound by Cyril A. Clarke
Jaundice ofnewbom infants was described by several authors in the 17th century. The condition, however, was usually thought of as being similar to adult jaundice and due ro occlusion of the bile ducts by 'glutinous humours'. On the other hand, some writers reported on the fact that more than one consecutive baby was often affected, and there is a classic example of the disease in twins written by Louyse Bourgeois, the midwife of Marie de Medici, in 1609. It was not until early in the 20th century that it was realised that the common link between these familial cases was anaemia, and later still that this was of the haemolytic type. The breakthrough, in terms of an idea, came in 1938, when Darrow postulated that the baby's red cells were destroyed by an immune reaction on the part of the mother, the result of immunisation by paternal factors in the fetus. Shortly afterwards Wiener discovered an entirely new blood group system, 'Rh', and it was found that it was in compatibility within this system that was responsible for the vast majority of cases of haemolytic disease of the newborn. Section 1 Discovery of the Rh blood group system and related matters.- 1. Icterus gravis (Erythroblastosis) neonatorum.- 2. An unusual case of intra-group agglutination.- 3. An agglutinable factor in human blood recognised by immune sera for Rhesus blood.- 4. Hemolytic reactions following transfusions of blood of the homologous group, with three cases in which the same agglutinogen was responsible.- 5. The role of iso-immunization in the pathogenesis of erythroblastosis fetalis.- 6. Serological factors as possible causes in spontaneous abortions (extracts).- 7. Blood Groups in Man (extract).- 8. A new test (blocking test) for Rh sensitization.- 9. An incomplete antibody in human serum.- 10. Detection of weak and “incomplete” Rh agglutinins: a new test.- 11. Use of trypsin in the detection of incomplete anti-Rh antibodies.- 12. Anti-Rh serum nomenclature.- 13. Anti-Rh serum nomenclature.- 14. Heredity of the Rh blood types (extract).- 15. Some notes on Fisher’s contributions to human blood groups (extract).- Section II Methods of treating the established disease.- 16. Erythroblastosis foetalis or haemolytic disease of the newborn.- 17. Controlled trials of the treatment of haemolytic disease of the newborn.- 18. Composition of liquor amnii in haemolytic disease of newborn.- 19. The antenatal prediction of haemolytic disease of the newborn (extract).- 20. Intrauterine transfusion of foetus in haemolytic disease.- Section III Prophylaxis.- 21. The influence of mother-child ABO incompatibility on Rh immunisation.- 22. Demonstration von fetalem Hämoglobin in den Erythrocyten eines Blutausstrichs.- 23. Foetal erythrocytes in the maternal circulation.- 24. The Sources of Invention (extract).- 25. Erythroblastosis (extract).- 26. Experimental studies on the prevention of Rh-haemolytic disease.- 27. Experimental isosensitization to hemoantigens in man (abstract).- 28. Experimental isiommunization to hemoantigens in man (extract).- 29. Current Concepts: Antepartum management of Rh Hemolytic disease (extract).- 30. Successful prevention of experimental Rh sensitization in man with an anti-Rh gamma2-globulin antibody preparation.- 31. Untersuchungen zur Serologischen Prophylaxe der Rh-Sensibilisierung.- 32. Further experimental studies on the prevention of Rh haemolytic disease.- 33. Prevention of Rh-haemolytic disease: a third report.- 34. Prevention of Rh-haemolytic disease: results of the clinical trial.- 35. Results of clinical trials of RhoGAM in women.- 36. The suppression of Rh immunisation by passively administered human immunoglobulin (IgG) anti-D (anti-Rho).- 37. The estimation of the concentration and equilibrium constant of anti-D..- 38. Suppression of primary Rh immunization by passively-administered antibody: Experiments in volunteers.- 39. Prevention of Rh haemolytic disease. Editorial.- 40. The pathogenesis and prevention of Rh immunization.- 41. Prevention of Rh-haemolytic disease..- 42. Prevention of Rh haemolytic disease..- 43. Studies on Rh prophylaxis. Relationship between doses of anti-Rh and size of antigenic stimulus.- 44. Prevention of Rh-haemolytic disease: final results of the “high-risk” clinical trial.- 45. Prevention of Rh-haemolytic disease; results of the Liverpool “low-risk” clinical trial.- 46. Report of MRC anti-D Working Party.- 47. Effectiveness of Rh Prophylaxis.- 48. Rh and iso-immunisation: Summary of a 1974 Workshop.- Further References and Addresses.